KIT in ovarian carcinoma: disillusion about a potential therapeutic target

J Natl Cancer Inst. 2003 Jul 2;95(13):1009-10. doi: 10.1093/jnci/95.13.1009-a.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Benzamides
  • Enzyme Inhibitors / therapeutic use
  • Female
  • Humans
  • Imatinib Mesylate
  • Immunohistochemistry
  • Mutation*
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / genetics*
  • Ovarian Neoplasms / pathology
  • Piperazines / therapeutic use
  • Polymerase Chain Reaction / methods
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Pyrimidines / therapeutic use
  • Receptor Protein-Tyrosine Kinases / genetics*

Substances

  • Antineoplastic Agents
  • Benzamides
  • Enzyme Inhibitors
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases
  • Receptor Protein-Tyrosine Kinases